• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Euro Surveill. Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October ? December 2009

Giuseppe

Emeritus
Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October ? December 2009 (Euro Surveill., abstract, edited)


[Source: Eurosurveillance, full text: <cite cite="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19678">Eurosurveillance - View Article</cite>. Abstract, edited.]

Eurosurveillance, Volume 15, Issue 40, 07 October 2010

Research articles

Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October ? December 2009

J McVernon 1,2, K Laurie 2,3, T Nolan 1, R Owen 4, D Irving 5, H Capper 5, C Hyland 5, H Faddy 5, L Carolan 3, I Barr 3, A Kelso 3
1. Vaccine & Immunisation Research Group, Melbourne School of Population Health, University of Melbourne and Murdoch Children?s Research Institute, Melbourne, Australia
2. These authors contributed equally to this work
3. World Health Organization Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia
4. Surveillance Branch, Office of Health Protection, Australian Government Department of Health and Ageing, Canberra, Australia
5. Research and Business Development Division, Australian Red Cross Blood Service, Sydney, Australia

Citation style for this article: McVernon J, Laurie K, Nolan T, Owen R, Irving D, Capper H, Hyland C, Faddy H, Carolan L, Barr I, Kelso A. Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October ? December 2009. Euro Surveill. 2010;15(40):pii=19678. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19678

Date of submission: 19 March 2010


Assessment of the severity of disease due to the 2009 pandemic influenza A(H1N1) in Australian states and territories has been hampered by the absence of denominator data on population exposure. We compared antibody reactivity to the pandemic virus using haemagglutination inhibition assays performed on plasma specimens taken from healthy adult blood donors (older than 16 years) before and after the influenza pandemic that occurred during the southern hemisphere winter. Pre-influenza season samples (April ? May 2009, n=496) were taken from donation collection centres in North Queensland (in Cairns and Townsville); post-outbreak specimens (October ? November 2009, n=779) were from donors at seven centres in five states. Using a threshold antibody titre of 40 as a marker of recent infection, we observed an increase in the influenza-seropositive proportion of donors from 12% to 22%, not dissimilar to recent reports of influenza A(H1N1)-specific immunity in adults from the United Kingdom. No significant differences in seroprevalence were observed between Australian states, although the ability to detect minor variations was limited by the sample size. On the basis of these figures and national reporting data, we estimate that approximately 0.23% of all individuals in Australia exposed to the pandemic virus required hospitalisation and 0.01% died. The low seroprevalence reported here suggests that some degree of prior immunity to the virus, perhaps mediated by broadly reactive T-cell responses to conserved influenza viral antigens, limited transmission among adults and thus constrained the pandemic in Australia.

-
------
 
Back
Top Bottom